

### REMARKS

Applicant respectfully traverses the restriction requirement of claims 1-71 as being drawn to eight distinct inventions. However, in order to be fully responsive to the Office Communication, Applicant elects Group I, claims 1-34, drawn to a method of screening for modulating agents.

As indicated in the Office Action, the Examiner further requires, for examination purposes, the election of the following species: (A) a type of PPIase inhibitor from among those claimed in claims 9 and 61; (B) a type of endpoint assay from among those claimed in claim 11; (C) a type of recombinant protein or peptide from among those claimed in claim 16; (D) the type of protein or peptide from among those claimed in claims 22 and 65; (E) the type of PPIase from among those claimed in claims 24 and 60; (F) the type of Homer protein from those claimed in claim 28; (G) the type of neurodisorders from among those claimed in claims 32, 42-45, and 59; (H) the type of disorder from among those claimed in claims 34, 47 and 55; and (I) the type of hematological disorder from among those claimed in claims 49 and 57.

Applicant elects: (A) **FK506** as the PPIase inhibitor, (B) **modulation of Trp channels** as the endpoint assay, (C) **NP776901** as the recombinant protein or peptide, (D) **TrpC1** as the type of protein or peptide, (E) **FKBP family** as the type of PPIase; (F) **NP004829** as the type of Homer protein; (G) **neurological pathologies related to neurodegeneration** as the type of neurodisorders; and (H) **CNS inflammatory disorder** as the type of disorder. Applicant submits that election of a type of hematological disorder (I) is rendered moot as a result of the election of Group I.

Upon allowance of a generic claim, Applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim. The Office has indicated that claims 1, 46, 48 and 50 are generic.

In re Application of:  
Paul F. Worley  
Application No.: 10/518,941  
Filed: November 21, 2005  
Page 3

PATENT  
Attorney Docket No.: JHU1880-1

The Examiner is invited to contact Applicant's undersigned representative if there are any questions relating to this application.

Check number 584255 in the amount of \$510.00 is enclosed as payment for the Three-Month Extension of Time fee. No other fee is deemed necessary with the filing of this paper. However, the Commissioner is hereby authorized to charge any fees that are required, or credit any overpayments to Deposit Account No. 07-1896 referencing the above-identified attorney docket number. A copy of the Transmittal Sheet is enclosed.

Respectfully submitted,

Date: December 22, 2006



---

Antony M. Novom, J.D.  
Registration No.: 45,517  
Telephone: (858) 638-6641  
Facsimile: (858) 677-1465

DLA PIPER US LLP  
4365 Executive Drive, Suite 1100  
San Diego, California 92121-2133  
USPTO Customer No. 28213